[HTML][HTML] Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology

SM Tinsley, C Grande, K Olson, L Plato… - Journal of the …, 2018 - ncbi.nlm.nih.gov
Biosimilars are biologic products that are highly similar, but not identical, to a licensed
reference (or" originator") biologic product. These agents have the potential to provide …

The language of biosimilars: clarification, definitions, and regulatory aspects

P Declerck, R Danesi, D Petersel, I Jacobs - Drugs, 2017 - Springer
Biologic therapies have revolutionized treatment of a number of diseases. Patents and
exclusivity for a number of biologics are expiring. This has created the opportunity for the …

Biosimilars: hope and concern

CE Emmanouilides, MI Karampola… - Journal of Oncology …, 2016 - journals.sagepub.com
As patents of the first introduced biologic therapeutics in oncology have begun to expire,
competing pharmaceutical companies are allowed to produce and market the same protein …

[PDF][PDF] The future of biological therapy: a pathway forward for biosimilars

RO Dolinar, MS Reilly - GaBI J, 2013 - gabi-journal.net
Biologicals are large, complex molecule drugs that treat serious illnesses. They are created
using proprietary and unique processes involving living cells, and range from sugars and …

[HTML][HTML] The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019

HN Kang, R Thorpe, I Knezevic, CDRZ Blades… - Biologicals, 2020 - Elsevier
Abstract The World Health Assembly in 2014 adopted a resolution that mandates both
Member States and the WHO Secretariat to facilitate access to biotherapeutic products in a …

Biosimilars in an era of rising oncology treatment options

M Peeters, D Planchard, M Pegram, J Gonçalves… - Future …, 2021 - Taylor & Francis
New diagnostic technologies, including molecular profiling, have enabled advances in
treatments of various cancers; this has significantly improved clinical outcomes, including …

Biosimilars: science, implications, and potential outlooks in the Middle East and Africa

RA Batran, M Elmoshneb, AS Hussein… - … : Targets and Therapy, 2022 - Taylor & Francis
Biosimilars are biological products that efficiently replicate the function of the originator
products. They have changed the prognosis of millions of patients with many serious …

Are biosimilars really generics?

A Misra - Expert opinion on biological therapy, 2010 - Taylor & Francis
Importance of the field: Ever since the formation of the first biotechnology company almost
three decades ago, more than 150 biopharmaceutical products have been marketed across …

Biosimilars–science, status, and strategic perspective

GB Kresse - European Journal of Pharmaceutics and …, 2009 - Elsevier
Biopharmaceuticals based on recombinant proteins have started to go off-patent, opening
the way for other manufacturers to place follow-on products to the market. Meanwhile it has …

Biosimilars and the European experience: implications for the United States

F Megerlin, R Lopert, K Taymor, JH Trouvin - Health Affairs, 2013 - healthaffairs.org
Biologics are medicines derived from a biological source. Their high prices and rapid uptake
have raised hopes that with the gradual expiration of patents on the first generations of …